Pfizer Press Release:

Pfizer Prices $4.0 Billion Debt Offering

Tuesday, May 28, 2013 5:58 pm EDT

Dateline:

NEW YORK

EmailPDFPrintRSS

Public Company Information:

NYSE:

PFE

US7170811035

"Forward-Looking Information and Factors That May Affect Future Results"

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of five tranches of notes:

• $750,000,000 aggregate principal amount of 0.900% notes due 2017
• $1,000,000,000 aggregate principal amount of 1.500% notes due 2018
• $500,000,000 aggregate principal amount of floating rate notes due 2018
• $1,000,000,000 aggregate principal amount of 3.000% notes due 2023
• $750,000,000 aggregate principal amount of 4.300% notes due 2043

Pfizer intends to use the net offering proceeds for general corporate purposes, including (i) the repayment at maturity of the €1.85 billion outstanding of its 3.625% notes due June 2013; and (ii) pre-funding the repayment of a portion of its outstanding 4.50% notes due February 2014 and 5.50% notes due February 2014. Pfizer may use funds that are not immediately needed for these purposes to temporarily invest in short-term marketable securities or repay a portion of its outstanding commercial paper. The closing of the offering is expected to occur on June 3, 2013, subject to satisfaction of customary closing conditions.

Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, Goldman, Sachs & Co. and RBS Securities Inc. are acting as joint book-running managers for the offering.

The offering of these securities is being made only by means of a prospectus. Copies may be obtained by calling Citigroup Global Markets Inc. toll-free at 1-800-831-9146, Credit Suisse Securities (USA) LLC, Prospectus Department, toll-free at 1-800-221-1037, Goldman, Sachs & Co. toll-free at 1-866-471-2526 or RBS Securities Inc toll-free at 1-866-884-2071.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the notes, nor will there be any sale of the notes in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

About Pfizer

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.